Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed by €21.5 million in ...
Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system-a group of proteins that ...
Follow-up on phase 1 study of AT101, a novel anti-CD19 chimeric antigen receptor cell therapy (CAR-T) in patients with relapsed or refractory (r/r) b-cell non-Hodgkin lymphoma. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results